BioCorRx Inc. (BICX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
2390 EAST ORANGEWOOD AVENUE ANAHEIM, CA 92806 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 8093 - Specialty Outpatient Facilities, Not Elsewhere Classified (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 88 | 0 | 8 | 101 | 156 | ||||
| Cash and cash equivalent | 88 | 0 | 8 | 101 | 156 | ||||
| Receivables | 1 | 12 | |||||||
| Inventory, net of allowances, customer advances and progress billings | |||||||||
| Inventory | |||||||||
| Prepaid expense | 30 | 39 | 54 | 29 | 45 | 72 | |||
| Other undisclosed current assets | 314 | 110 | 21 | 141 | 5 | ||||
| Total current assets: | 118 | 353 | 172 | 152 | 187 | 246 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 199 | 209 | 218 | 71 | 97 | 177 | |||
| Property, plant and equipment | 19 | 32 | 38 | 45 | 51 | 57 | |||
| Intangible assets, net (including goodwill) | 8 | 8 | 8 | 9 | 9 | 9 | |||
| Goodwill | |||||||||
| Intangible assets, net (excluding goodwill) | 8 | 8 | 8 | 9 | 9 | 9 | |||
| Other undisclosed noncurrent assets | 42 | 42 | 42 | 42 | 45 | 45 | |||
| Total noncurrent assets: | 268 | 290 | 307 | 166 | 202 | 289 | |||
| TOTAL ASSETS: | 386 | 644 | 479 | 317 | 389 | 534 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 5,575 | 5,682 | 5,330 | 4,977 | 4,649 | 4,444 | |||
| Accounts payable | 3,024 | 3,096 | 2,830 | 2,773 | 2,473 | 2,390 | |||
| Accrued liabilities | 1,329 | 1,330 | 1,341 | 1,294 | 1,268 | 1,246 | |||
| Other undisclosed accounts payable and accrued liabilities | 1,223 | 1,256 | 1,159 | 910 | 907 | 808 | |||
| Deferred revenue | 7 | ||||||||
| Debt | 1,343 | 1,288 | 1,001 | 803 | 607 | 408 | |||
| Accrued reclamation costs | 43 | ||||||||
| Other undisclosed current liabilities | 1,290 | 1,254 | 984 | 1,388 | 1,132 | 1,088 | |||
| Total current liabilities: | 8,208 | 8,224 | 7,315 | 7,168 | 6,431 | 5,947 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 159 | 169 | 398 | 4 | 15 | 74 | |||
| Deferred revenue | 4 | 4 | 4 | ||||||
| Lease deposit liability | 218 | ||||||||
| Operating lease, liability | 159 | 169 | 180 | 11 | 70 | ||||
| Other undisclosed noncurrent liabilities | 4,374 | 4,253 | 3,914 | 4,013 | 3,895 | 3,774 | |||
| Total noncurrent liabilities: | 4,534 | 4,422 | 4,311 | 4,017 | 3,910 | 3,848 | |||
| Total liabilities: | 12,741 | 12,647 | 11,626 | 11,186 | 10,341 | 9,795 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (12,120) | (11,831) | (11,001) | (10,739) | (9,824) | (9,132) | |||
| Common stock | 13 | 11 | 10 | 9 | 9 | 9 | |||
| Common stock, value, subscriptions | 100 | 100 | 100 | 100 | 100 | 100 | |||
| Additional paid in capital | 70,954 | 70,080 | 69,424 | 68,471 | 68,149 | 67,872 | |||
| Accumulated deficit | (83,209) | (82,045) | (80,557) | (79,340) | (78,103) | (77,134) | |||
| Other undisclosed equity, attributable to parent | 22 | 22 | 22 | 22 | 22 | 22 | |||
| Equity, attributable to noncontrolling interest | (235) | (172) | (146) | (130) | (129) | (128) | |||
| Total equity: | (12,355) | (12,003) | (11,148) | (10,868) | (9,953) | (9,260) | |||
| TOTAL LIABILITIES AND EQUITY: | 386 | 644 | 479 | 317 | 389 | 534 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 4 | 4 | 19 | 10 | ||||
| Cost of revenue | (2) | (13) | (4) | |||||
| Gross profit: | 4 | 2 | 6 | 6 | ||||
| Operating expenses | (1,125) | (1,660) | (1,373) | (972) | (842) | (972) | ||
| Other undisclosed operating income | 2 | 13 | 4 | |||||
| Operating loss: | (1,125) | (1,660) | (1,369) | (969) | (823) | (962) | ||
| Nonoperating income (expense) | (103) | 147 | 135 | (269) | (146) | 95 | ||
| Other nonoperating income (expense) | (1) | 5 | 138 | 13 | ||||
| Interest and debt expense | (122) | (77) | (34) | (37) | ||||
| Loss from continuing operations before equity method investments, income taxes: | (1,349) | (1,590) | (1,234) | (1,272) | (969) | (904) | ||
| Other undisclosed income from continuing operations before income taxes | 122 | 77 | 34 | 37 | ||||
| Net loss: | (1,228) | (1,513) | (1,234) | (1,237) | (969) | (867) | ||
| Other undisclosed net income attributable to parent | ||||||||
| Net loss attributable to parent: | (1,228) | (1,513) | (1,234) | (1,237) | (969) | (867) | ||
| Other undisclosed net income available to common stockholders, basic | 106 | |||||||
| Net loss available to common stockholders, diluted: | (1,122) | (1,513) | (1,234) | (1,237) | (969) | (867) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (1,228) | (1,513) | (1,234) | (1,237) | (969) | (867) | ||
| Comprehensive loss, net of tax, attributable to parent: | (1,228) | (1,513) | (1,234) | (1,237) | (969) | (867) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.